2021
DOI: 10.7759/cureus.17565
|View full text |Cite
|
Sign up to set email alerts
|

Review of the Literature on Ocular Complications Associated With Aromatase Inhibitor Use

Abstract: Aromatase inhibitors (AIs), such as anastrozole, letrozole, and exemestane, are commonly used as adjuvant endocrine therapy in hormone-receptive breast cancer in postmenopausal women. Their adverse effects are well documented, except for visual disturbances. The purpose of this study was to review the current literature on ocular disease linked to AI use. Due to the scarcity of published data, any suggested ophthalmic adverse events were included to increase awareness of these drugs. The ocular side effects of… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
7
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(7 citation statements)
references
References 20 publications
0
7
0
Order By: Relevance
“…The literature demonstrates evidence of retinopathy secondary to Anastrozole therapy and other AIs. The management includes stopping the causing medication and providing steroidal treatment [ 5 ].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The literature demonstrates evidence of retinopathy secondary to Anastrozole therapy and other AIs. The management includes stopping the causing medication and providing steroidal treatment [ 5 ].…”
Section: Discussionmentioning
confidence: 99%
“…Prompt ophthalmologic evaluation and high index of suspicion is recommended when assessing patients with visual disturbances currently under treatment with AIs. Larger prospective studies are needed to analyze the severity of ocular complications [ 5 ].…”
Section: Discussionmentioning
confidence: 99%
“…The incidence of ocular side effects from the use of anastrozole or other AIs is rare but documented within the literature, describing various ocular pathologies and symptoms. The literature further displays that ocular complications linked to the use of anastrozole are slightly more prevalent compared to other AIs [ 4 ].…”
Section: Discussionmentioning
confidence: 99%
“…Studies have identified retinopathy issues such as crystalline retinopathy, hemicentral retinal artery occlusion, and retinal hemorrhages associated with these third-generation AIs. Furthermore, ocular surface conditions, including corneal epithelial changes, blepharitis, and keratitis, have been observed in patients taking AIs [ 4 ]. Although these ocular side effects are likely infrequent, we emphasize the importance of maintaining a high level of clinical suspicion when evaluating patients who experience visual symptoms while on AIs.…”
Section: Introductionmentioning
confidence: 99%
“…The oncologic therapy protocol often includes several different drugs, as in our case. There is some literature available regarding AI-related ocular diseases and TXT [ 4 , 5 , 15 ], but no HER or PER data. However, large prospective studies are lacking.…”
Section: Discussionmentioning
confidence: 99%